Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

Oncology stocks

Ready to invest in the cancer industry? Consider these 9 stocks.

The best oncology stocks depend on your portfolio and investment goals — while volatility can be ideal for day traders, long-term investors will want to look to stocks with steadier gains over time.

How to buy oncology stocks

Sign up with an online broker or platform to invest in one of more of these oncology stocks.

  1. Compare share trading platforms. Use our comparison table to narrow down top brokers by fees and bonuses.
  2. Open and fund your brokerage account. You’ll need personal and financial details, like your contact and bank information.
  3. Search for the stock you're interested in. Find the stock by name or ticker symbol, like AMGN or BMY.
  4. Decide on how many to buy. Some brokers will allow you to purchase fractional shares, while others require you to purchase whole shares.
  5. Choose an order type. Invest in the oncology stocks now with a market order or use a limit order to delay your purchase until the stock reaches your desired price.
  6. Buy the stock. Tap or click the Buy button on your brokerage account. Once you’ve invested in the cancer industry, track how your stock performs to decide when it’s time to sell.

Take a deeper dive into oncology stocks

We round up a selection of stocks in or related to the cancer industry, weighting the list more heavily towards popular mid- and large-cap US stocks.

1. Amgen (AMGN)

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas.

Amgen stock opened the day at $242.62 after a previous close of $242.46. The latest price was $241.54 (25 minute delay). Amgen is listed on the NASDAQ, has a trailing 12-month revenue of around USD25.2 billion and employs 24,300 staff.

  • Market capitalization: $139,306,369,024
  • P/E ratio: 20.0828
  • PEG ratio: 1.7911

Back to top


2. Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis.

Bristol-Myers Squibb Company stock opened the day at $68.15 after a previous close of $68.15. The latest price was $67.87 (25 minute delay). Bristol-Myers Squibb Company is listed on the NYSE, has a trailing 12-month revenue of around USD$42.8 billion and employs 30,250 staff.

  • Market capitalization: $152,168,038,400
  • PEG ratio: 31.9253

Back to top


3. Five Prime Therapeutics (FPRX)

Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company, focuses on the development of immuno-oncology and targeted cancer therapies. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b to treat patients with gastric or gastroesophageal junction and GEJ cancer; FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28 that is in Phase Ia/1b clinical trial for patients with solid tumors; and BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase I/II clinical trial in combination with Opdivo in patients with advanced malignant tumors.

Five Prime Therapeutics is listed on the NASDAQ, has a trailing 12-month revenue of around USD$13.2 million and employs 51 staff.

  • Market capitalization: $1,769,735,936
  • PEG ratio: 0.14

Back to top


4. Gilead Sciences (GILD)

Gilead Sciences, Inc. , a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.

Gilead Sciences stock opened the day at $68.70 after a previous close of $69.83. The latest price was $68.29 (25 minute delay). Gilead Sciences is listed on the NASDAQ, has a trailing 12-month revenue of around USD$25.6 billion and employs 13,600 staff.

  • Market capitalization: $87,579,385,856
  • P/E ratio: 290.9583
  • PEG ratio: 0.494

Back to top


5. Novartis (NVS)

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers.

Novartis stock opened the day at $92.10 after a previous close of $92.35. The latest price was $92.74 (25 minute delay). Novartis is listed on the NYSE, has a trailing 12-month revenue of around USD$51.6 billion and employs 109,000 staff.

  • Market capitalization: $205,534,052,352
  • P/E ratio: 23.281
  • PEG ratio: 2.5959

Back to top


6. Cardiff Oncology (CRDF)

Cardiff Oncology, Inc. , a clinical-stage biotechnology company, develops drugs for the treatment of cancer. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic colorectal cancer in combination with FOLFIRI and Avastin.

Cardiff Oncology stock opened the day at $7.78 after a previous close of $7.66. The latest price was $7.87 (25 minute delay). Cardiff Oncology is listed on the NASDAQ, has a trailing 12-month revenue of around USD$369,993 and employs 11 staff.

  • Market capitalization: $212,544,880

Back to top


7. Surface Oncology (SURF)

Surface Oncology, Inc. , a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 (IgG4) monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; SRF813 targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8 to deplete immuno-suppressive cells.

Surface Oncology stock opened the day at $7.14 after a previous close of $7.12. The latest price was $7.12 (25 minute delay). Surface Oncology is listed on the NASDAQ, has a trailing 12-month revenue of around USD$89.2 million and employs 51 staff.

  • Market capitalization: $264,798,432
  • P/E ratio: 11.5261

Back to top


8. Trillium Therapeutics (TRIL)

Trillium Therapeutics Inc. , a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides.

Trillium Therapeutics stock opened the day at $8.67 after a previous close of $8.63. The latest price was $8.50 (25 minute delay). Trillium Therapeutics is listed on the NASDAQ, has a trailing 12-month revenue of around USD$148,000 and employs 33 staff.

  • Market capitalization: $673,484,608
  • PEG ratio: 0

Back to top


9. Mersana Therapeutics (MRSN)

Mersana Therapeutics, Inc. , a clinical stage biopharmaceutical company, focuses on the development of antibody drug conjugates (ADC) for cancer patients with unmet need. The company develops XMT-1536, a Dolaflexin ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer and non-small cell lung cancer (NSCLC) adenocarcinoma; and XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumors, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma.

Mersana Therapeutics stock opened the day at $12.90 after a previous close of $12.85. The latest price was $12.88 (25 minute delay). Mersana Therapeutics is listed on the NASDAQ, has a trailing 12-month revenue of around USD$828,000 and employs 110 staff.

  • Market capitalization: $813,177,408
  • PEG ratio: 0

Back to top

Compare trading platforms

Compare online trading platforms by fees, asset types and bonuses to find the best for your investment in oncology stocks.
Name Product Asset types Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Robinhood
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Public
Stocks, ETFs
Download and sign up with Public.com; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Webull
Stocks, Options, ETFs
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
TD Ameritrade
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
TD Ameritrade features $0 commission for online stock trades. Online options fees are $0.65/contract.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Bottom line

While it’s possible to turn a profit investing in oncology stocks, keep in mind that — like any investment — oncology stocks are not immune to risk. These stocks are subject to fluctuating conditions — both in the market and in the cancer industry, so carefully vet your picks before you invest. And if you’re new to investing, or if it’s been awhile since you’ve taken a critical look at your investing accounts, compare brokers to make sure you’re getting the best features in your trading account.

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site